Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HighFive
2026-525497-18-00Phase 3Authorised
- Sponsor
- AIO-Studien
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AIO-Studien. Primary endpoint: Progression-free survival. Planned start Oct 2026; status: authorised.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2026-525497-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525497-18-00.